Inclusion Criteria:

- Visible and histologically proven actinic keratosis

- Prepared and able to give written informed consent

- ≥ 18 -80 years of age

- Prepared and comply with all study requirements, including the following: application
of gel on the treatment area twice a day, 5 / 7 clinic visits during the prestudy,
treatment, posttreatment, and follow-up period

- Pre- and posttreatment biopsy for histological confirmation (of clearance) of actinic
keratosis diagnosis

Exclusion Criteria:

- Data of clinically significant, unstable, cardiovascular or haematologic, hepatic,
neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or
diseases

- Known allergies to any excipient in the study drug

- Any dermatological disease and/or condition in the treatment or surrounding area (3
cm distances from treatment area) that may be exacerbated by treatment with
diclofenac or cause difficulty with examination

- Active chemical dependency or alcoholism, as assessed by the investigator

- Currently participating in another clinical study or have completed another clinical
study with an investigational drug within the past 30 days

- Received topical treatment at the treatment area with imiquimod or 5-FU within a time
period of 1 month

- Invasive tumours within the treatment area, e.g. merkel cell carcinoma, squamous cell
carcinoma, basal cell carcinoma, the latter is accepted if completely surgically
removed